Some 2seventy bio team members that have been working on the haemophilia A program will now be joining Novo Nordisk. Image Credit: Andrey_Popov/Shutterstock.

US-based 2seventy bio has completed an asset purchase agreement (APA) to divest its haemophilia A candidate to Novo Nordisk.

2seventy bio will potentially receive up to $40m under the deal, which brings an end to a research agreement established between the companies in 2019. The deal focused on developing a gene editing therapy for people with haemophilia A.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Haemophilia is a rare disorder in which blood does not clot in a typical way because it doesn’t have enough blood-clotting proteins.

Novo Nordisk will also receive rights to 2seventy’s MegaTAL in vivo gene editing technology for its applications in projects other than those involving oncology and autoimmune disorders.  

2seventy bio team members currently involved in the program will join Novo Nordisk to continue advancing the technology.

“Novo Nordisk has been a valued partner over the past five years, and we are confident that under their leadership, the promise of developing a new treatment approach for patients living with hemophilia A will continue to progress,” commented 2seventy bio CEO Chip Baird.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

2seventy bio has said it will now focus exclusively on the continued development and commercialisation of Abecma (idecabtagene vicleucel), its BCMA-targeted chimeric antigen receptor (CAR)-T cell therapy for multiple myeloma (MM), which it developed in collaboration with Bristol Myers Squibb (BMS).

Abecma gained approval from the US Food and Drug Administration (FDA) in April 2024.

An FDA committee voted eight to three in favour of approving Abecma, despite recent controversies surrounding the safety of CAR-T therapies.